Table 3.
Prime | Boost | |||
Volume of lesions (mm3) | Degree of liquefaction (5–7 days) | Volume of lesions (mm3) | Degree of liquefaction (2–3 days) | |
P10* 5 × 107 CFU | 750.0 ± 34.6 | ++ | 1008.8 ± 123.9 | ++ |
P19* 5 × 107 CFU | 720.0 ± 48.9 | ++ | 970.0 ± 61.8 | +++ |
P17* 5 × 107 CFU | 680.0 ± 123.3 | ++ | 896.5 ± 32.5 | ++ |
P15* 5 × 107 CFU | 677.5 ± 85.0 | ++ | 882.7 ± 62.2 | +++ |
P18* 5 × 107 CFU | 676.5 ± 55.3 | +++ | 875.0 ± 132.3 | ++++ |
P14* 5 × 107 CFU | 675.0 ± 115.3 | +++ | 862.5 ± 91.9 | ++++ |
PolyG 5 × 107 CFU | 578.5 ± 69.1 | ++ | 852.5 ± 34.6 | +++ |
P16 5 × 107 CFU | 625.0 ± 146.4 | ++ | 845.0 ± 49.4 | +++ |
P11 5 × 107 CFU | 577.5 ± 31.8 | ++ | 843.8 ± 91.9 | ++ |
P13 5 × 107 CFU | 562.5 ± 25.0 | + | 812.5 ± 65.0 | +++ |
P12 5 × 107 CFU | 580.0 ± 77.8 | ++ | 827.5 ± 61.8 | ++ |
P20 5 × 107 CFU | 575.0 ± 28.9 | + | 791.3 ± 52.6 | ++ |
H37Ra 5 x 107 CFU | 566.3 ± 79.7 | + | 785.5 ± 90.0 | ++ |
p < 0.05 P10, P14, P15, P17, P18, P19 vs. H37Ra control.